Mein Warenkorb

Transferrin R

Transferrin R Molekülinformation

Englischer NameTransferrin receptor protein 1Anzahl der inverkehr gebrachten Arzneimittel1
Anzahl der klinischen Arzneimittel15Target-AliasTFRC,T9,sTfR,Transferrin receptor protein 1,TR,Transferrin Receptor,P90,Transferrin Receptor (P90, CD71),CD71 Antigen,IMD46,CD71,TfR1,Trfr,TfR
Höchste Forschungs- und EntwicklungsphaseApproved
Englischer NameTransferrin receptor protein 1
Target-AliasTFRC,T9,sTfR,Transferrin receptor protein 1,TR,Transferrin Receptor,P90,Transferrin Receptor (P90, CD71),CD71 Antigen,IMD46,CD71,TfR1,Trfr,TfR
Anzahl der inverkehr gebrachten Arzneimittel1
Anzahl der klinischen Arzneimittel15
Höchste Forschungs- und EntwicklungsphaseApproved

Transferrin R Produktliste

  • Attribut

    Protein (16)Cell (1)

  • Produktbibliothek

    Online (17)

  • Spezies

    Human (7)Cynomolgus (4)Mouse (4)Rat (2)

  • Etikett

    His Tag (7)His Tag & Avi Tag (4)Fc Tag (3)Tag Free (2)Fc Tag & Avi Tag (1)

  • Marker

    Unconjugated (8)Biotin-labeled (8)- (1)

Transferrin R Molekülhintergrund

CD antigen CD71 is also known as Transferrin receptor protein 1, TfR, sTfR, p90, TfR1, Trfr, which belongs to the peptidase M28 family and M28B subfamily. CD71 /TFR contains one PA (protease associated) domain. CD71 / TfR1 is required for iron delivery from transferrin to cells. CD71 is a potential new target in cases of human leukomia & lymphoma. CD71 /TFRC / TfR has been shown to interact with GABARAP and HFE.

Transferrin R Molekülalias

CD71,TFRC,TFR,sTfR,TfR1,Trfr,T9,p90

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
Human apotransferrin (Sanquin Blood Supply Foundation)Phase 3 ClinicalSanquin Plasma Products Bvbeta-Thalassemia; Iron Metabolism Disorders
Details
Delpacibart braxlosiranAOC1020Phase 3 ClinicalAvidity Biosciences IncFoot-and-Mouth Disease; Muscular Dystrophies; Muscular Dystrophy, Facioscapulohumeral
Details
Delpacibart eteddesiranAOC-1001; AOC 1001Phase 3 ClinicalAvidity Biosciences IncGenetic Diseases, Inborn; Heredodegenerative Disorders, Nervous System; Muscular Atrophy; Muscular Diseases; Muscular Disorders, Atrophic; Muscular Dystrophies; Musculoskeletal Diseases; Myotonia; Myotonic Disorders; Myotonic Dystrophy; Nervous System Diseases; Neurodegenerative Diseases; Neuromuscular Diseases
Details
TrontinemabRO-7126209; RG-6102Phase 3 ClinicalF. Hoffmann-La Roche LtdAlzheimer Disease
Details
CX-2029ABBV-2029; ABBV-CX-2029; CX-2029Phase 2 ClinicalAbbvie Inc, Cytomx Therapeutics IncCarcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Head and Neck Neoplasms; Lymphoma, Large B-Cell, Diffuse; Solid tumours
Details
Zeleciment rostudirsenDYNE251Phase 2 ClinicalDyne Therapeutics IncMuscular Dystrophy, Duchenne
Details
AOC-1044AOC-1044; AOC 1044Phase 2 ClinicalAvidity Biosciences IncMuscular Dystrophy, Duchenne
Details
JR-446JR-446Phase 2 ClinicalJcr Pharmaceuticals Co Ltd, Medipal Holdings CorpMucopolysaccharidosis III
Details
JR-441JR-441Phase 2 ClinicalJcr Pharmaceuticals Co LtdMucopolysaccharidosis III
Details
Lepunafusp alfaJR-171Phase 2 ClinicalJcr Pharmaceuticals Co LtdMucopolysaccharidosis I
Details
PPMX-T003PPMX-T003Phase 2 ClinicalPerseus Proteomics IncLeukemia; Polycythemia Vera
Details
INA-03INA03Phase 1 ClinicalInatherysLeukemia; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma
Details
PRX012-TfRPRX012-TfRPhase 1 ClinicalProthenaAlzheimer Disease
Details
KK-2260KK2260; KK-2260Phase 1 ClinicalKyowa Kirin Co LtdEsophageal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck
Details
ABX-1100ABX-1100Phase 1 ClinicalAro Biotherapeutics CoGlycogen Storage Disease Type II
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
Pabinafusp alfaJR-141ApprovedJcr Pharmaceuticals Co LtdJapanMucopolysaccharidosis IIJcr Pharmaceuticals Co Ltd2021-03-23Mucopolysaccharidosis II
Details

Produktrezensionen

  • ***a2026-05-29
    0Menschen mögen
    Was purchased for use in BLI, both for immobilization onto human fc binding sensors and as analyte with a biotin-labeled TfR-targeting nanobody on streptavidin. Retested for use after 1.5 years storage at -80 and still had full functional activity.
  • S*** 2025-11-18
    0Menschen mögen
    Used this material as a captured ligand in routine SPR testing on a Biacore. Material is clean, consistent, and easy to work with, and can be used to generate quality data
  • ZZ2022-10-11
    0Menschen mögen
    We needed this product for our antibody research. ACRO managed to get it to us much faster than we expected, which made our research work very accurate. cd71 is a potential new target in human leukemia and lymphoma cases. cd71 /TFRC / TfR has been shown to interact with GABARAP and HFE. I am very pleased with the product and the quick technical support.
Laden Sie mehr
  • Molekülinformation
  • Produktliste
  • Inverkehr gebrachte Arzneimittelinformation
  • Produktrezensionen
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns